CoChat

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Open access
Tschöp, Matthias, Nogueiras, Ruben, Ahrén, Bo · 2023 · Diabetologia

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. They also reduce body weight by inducing satiety through central actions. The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c. or oral administration. GLP-1 receptor agonism is also achieved by inhibitors of dipeptidyl peptidase-4 (DPP-4), which prevent the inactivation of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their raised levels after meal ingestion. Other developments in GLP-1 receptor agonism include the formation of small orally available agonists and compounds with the potential to pharmaceutically stimulate GLP-1 secretion from the gut. In addition, GLP-1/glucagon and GLP-1/GIP dual receptor agonists and GLP-1/GIP/glucagon triple receptor agonists have shown the potential to reduce blood glucose levels and body weight through their effects on islets and peripheral tissues, improving beta cell function and stimulating energy expenditure. This review summarises developments in gut hormone-based therapies and presents the future outlook for their use in type 2 diabetes and obesity. Graphical Abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-023-05929-0

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic illustration of monoagonists, dual agonists and triple agonists based on GLP-1, GIP and glucagon receptor activation alone or in combination. This figure is available as part of a downloadable slideset
Fig. 1 Schematic illustration of monoagonists, dual agonists and triple agonists based on GLP-1, GIP and glucagon receptor activation alone or in combination. This figure is available as part of a downloadable slidesetCC BY · PubMed Central
Fig. 2 The clinically most relevant mechanisms of action of GLP-1, glucagon and GIP. These provide the main basis for the actions of GLP-1 receptor agonists and dual and triple receptor agonists in the therapy of type 2 diabetes and obesity. This figure is available as part of a downloadable slideset
Fig. 2 The clinically most relevant mechanisms of action of GLP-1, glucagon and GIP. These provide the main basis for the actions of GLP-1 receptor agonists and dual and triple receptor agonists in the therapy of type 2 diabetes and obesity. This figure is available as part of a downloadable slidesetCC BY · PubMed Central
Fig. 3 Structures of formulations of GLP-1 receptor agonists [14, 15, 19–21, 26]. (a) GLP-1, (b) exenatide, (c) lixisenatide, (d) efpeglenatide, (e) liraglutide, (f) semaglutide, (g) dulaglutide, (h) albiglutide. Amino acids are illustrated in circles; red circles show amino acids that are different from those in GLP-1. The red arrow in (a) illustrates the site of DPP-4 inactivation. This figure is available as part of a downloadable slideset
Fig. 3 Structures of formulations of GLP-1 receptor agonists [14, 15, 19–21, 26]. (a) GLP-1, (b) exenatide, (c) lixisenatide, (d) efpeglenatide, (e) liraglutide, (f) semaglutide, (g) dulaglutide, (h) albiglutide. Amino acids are illustrated in circles; red circles show amino acids that are different from those in GLP-1. The red arrow in (a) illustrates the site of DPP-4 inactivation. This figure is available as part of a downloadable slidesetCC BY · PubMed Central
Fig. 4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90]. Amino acids are illustrated in circles; blue circles show amino acids that are identical to those in GLP-1; black circles show amino acids that are present in GIP and tirzepatide but not in GLP-1; red circles show amino acids that are identical in tirzepatide and exenatide (see Fig. 3b); and green circles show amino acids that are present in tirzepatide but not in GLP-1, GIP or exenatide. AiB, aminoisobutyric acid. This figure is available as part of a downloadable slideset
Fig. 4 Structures of (a) GLP-1, (b) GIP and (c) tirzepatide [19, 88, 90]. Amino acids are illustrated in circles; blue circles show amino acids that are identical to those in GLP-1; black circles show amino acids that are present in GIP and tirzepatide but not in GLP-1; red circles show amino acids that are identical in tirzepatide and exenatide (see Fig. 3b); and green circles show amino acids that are present in tirzepatide but not in GLP-1, GIP or exenatide. AiB, aminoisobutyric acid. This figure is available as part of a downloadable slidesetCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Research works printed but not linked: 1

  1. Ahrén B (2001) Inhibition of dipeptidyl peptidase-4 (DPP-4): a target to treat type 2 diabetes. Curr Enzyme Inh 7:206–217

Cited by

Metadata

Authors
Tschöp, M., Nogueiras, R., & Ahrén, B.
Affiliations
Helmholtz Munich (DE)
Venue
Diabetologia
Published
2023-05-20
Volume
66
Issue
10
Pages
1796-1808
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4377138246
Cited by
92
References
105
Citations by year
2026: 23 · 2025: 23 · 2024: 33 · 2023: 12
FWCI
3.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • Medicinska Fakulteten, Lunds Universitet (314314)
  • Lund University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, gastrointestinal hormones, type 2 diabetes, obesity, DPP-4 inhibitors, exendin-4, GIP/GLP-1 receptor agonist, insulin secretion, satiety, beta-cell function, energy expenditure, drug formulation
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Body Weight, Diabetes Mellitus, Type 2, Glucagon, Glucose, Humans, Obesity, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.